Cell Medica bags €68,8 in Series C British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection. more ➔
Avantium raised €103m in oversubscribed...According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277 … more ➔
NSCLC: Transgene launches cancer combo tes...Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer … more ➔
Allogenic stem cell transplant safe in hea...Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction. more ➔
Pharnext partners with Galapagos Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnext’s pleotherapy approach to new indications. more ➔
BerGenBio plans IPO and partners with MSD Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor … more ➔
Breath Therapeutics cashes in €43,5mInhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova. more ➔
PwC reports high productivity of UK Life S... The UK’s Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life sciences … more ➔
Roche restarts pivotal Gantenerumab testsMorphoSys AG has announced that its partner Roche plans to start two further pivotal Phase III studies with its licensed Alzheimer’s antibody Gantenerumab. more ➔
Sanofi and AZ ink €600m deal for RSV jab Sanofi’s vaccine arm Sanofi Pasteur has inked a deal with AstraZeneca’s biologics subsidiary MedImmune totaling €615m to acquire co-development rights for MEDI8897, a jab to prevent respiratory syncytial … more ➔
